These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 29667324)
1. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database. Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324 [TBL] [Abstract][Full Text] [Related]
2. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. Crosby M; Tadrous M; Gomes T Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249 [TBL] [Abstract][Full Text] [Related]
3. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. Aladul MI; Fitzpatrick RW; Chapman SR BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626 [TBL] [Abstract][Full Text] [Related]
4. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Jha A; Upton A; Dunlop WC; Akehurst R Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027 [TBL] [Abstract][Full Text] [Related]
5. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. Kim SC; Choi NK; Lee J; Kwon KE; Eddings W; Sung YK; Ji Song H; Kesselheim AS; Solomon DH Arthritis Rheumatol; 2016 May; 68(5):1076-9. PubMed ID: 26662931 [TBL] [Abstract][Full Text] [Related]
6. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea. Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032 [TBL] [Abstract][Full Text] [Related]
7. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. Mansell K; Bhimji H; Eurich D; Mansell H BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624 [TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924 [TBL] [Abstract][Full Text] [Related]
9. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Aladul MI; Fitzpatrick RW; Chapman SR Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834 [TBL] [Abstract][Full Text] [Related]
10. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Curtis JR; Xie F; Kay J; Kallich JD Arthritis Res Ther; 2019 Dec; 21(1):285. PubMed ID: 31831064 [TBL] [Abstract][Full Text] [Related]
11. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823 [TBL] [Abstract][Full Text] [Related]
12. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567 [TBL] [Abstract][Full Text] [Related]
13. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19. Chen HH; Yemeke T; Ozawa S PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282 [TBL] [Abstract][Full Text] [Related]
14. Biosimilars for the management of rheumatoid arthritis: economic considerations. Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center. Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088 [TBL] [Abstract][Full Text] [Related]
16. Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. Stajszczyk M; Obarska I; Jeka S; Batko B Ann Rheum Dis; 2023 Sep; 82(9):1171-1180. PubMed ID: 37328194 [TBL] [Abstract][Full Text] [Related]
17. Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price. González-Fernández M; Villamañán E; Jiménez-Nácher I; Moreno F; Plasencia C; Gaya F; Herrero A; Balsa A Int J Clin Pharm; 2018 Dec; 40(6):1528-1538. PubMed ID: 30196515 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis. Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614 [TBL] [Abstract][Full Text] [Related]
19. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb. Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602 [TBL] [Abstract][Full Text] [Related]
20. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]